Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiotropium
Drug ID BADD_D02443
Description Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Indications and Usage Used in the management of chronic obstructive pulmonary disease (COPD).
Marketing Status Not Available
ATC Code R03BB04
DrugBank ID DB01409
KEGG ID D01929
MeSH ID D000069447
PubChem ID 5487427
TTD Drug ID D0P1WA
NDC Product Code Not Available
Synonyms Tiotropium Bromide | Bromide, Tiotropium | 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide | Tiotropium | Spiriva | BA 679 BR | 679 BR, BA | BR, BA 679 | BA-679 BR | BA679 BR
Chemical Information
Molecular Formula C19H22NO4S2+
CAS Registry Number 186691-13-4
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Metabolic acidosis14.01.01.003--Not Available
Middle insomnia19.02.01.003; 17.15.03.0030.000243%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.0030.000365%Not Available
Mood altered19.04.02.007--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.001217%
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.0040.000243%Not Available
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.000095%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.0010.000487%
Nasal dryness22.04.03.0020.000365%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.0020.002312%Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Neoplasm16.16.02.0010.000159%Not Available
Neoplasm malignant16.16.01.0010.000508%Not Available
Nervousness19.06.02.0030.000852%Not Available
Neurogenic bladder20.03.03.001; 17.10.01.0020.000243%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Nightmare19.02.03.003--Not Available
Ocular hyperaemia06.04.05.0040.000487%Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema mouth23.04.01.008; 10.01.05.006; 07.05.04.0010.000243%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 16 Pages